Search results
This document presents official recommendations of the American Association for the Study of Liver Diseases (AASLD) on the surveillance, diagnosis, and treatment of hepatocellular carcinoma (HCC) occur-ring in the setting of adults with cirrhosis.
HBV DNA integrates into the host cellular genome in the majority of cases of chronic hepatitis B (CHB) and induces genetic damage. DNA integration in nontu-moral cells in patients with HCC suggests that genomic integration and damage precede the development of tumor.
Abstract. Background. Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, including Australia. The absence of a consensus clinical practice guideline (CPG) specific to HCC management poses challenges in reducing morbidity, mortality, and improving patient recovery.
hepatocellular carcinoma. Key content includes diagnostic criteria, staging of disease, treatment plans and follow-up. The ESMO CPGs are intended to provide you with a set of recommendations for the best standards of care, using evidence-based medicine.
5 mar 2021 · Download Full Issue. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. A. Vogel 1 ∙ E. Martinelli 2 on behalf of the ESMO Guidelines Committee. Download PDF.
31 sty 2019 · Hepatocellular carcinoma: ESMO Clinical Practice † Guidelines for diagnosis, treatment and follow-up. *Correspondence to: ESMO Guidelines Committee, ESMO Head Office, Via Ginevra 4, 6900 Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org. †Approved by the ESMO Guidelines Committee: August 2018.
Management of Hepatocellular Carcinoma: An Update Jordi Bruix1 and Morris Sherman2 Preamble The recommendations provided in this document pro-vide a data-supported approach to the diagnosis, staging and treatment of patients diagnosed with hepatocellular carcinoma (HCC). They are based on the following: (a)
